 |
|
Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women
Jacqueline Suk Danik, MD, MPH;
Nader Rifai, PhD;
Julie E. Buring, ScD;
Paul M Ridker, MD, MPH
JAMA. 2006;296:1363-1370.
Context Controversy exists as to whether lipoprotein(a), a lipoprotein with homology to plasminogen, is a clinically meaningful cardiovascular risk marker in women. There is also poor agreement among lipoprotein(a) levels obtained by different assays.
Objective To determine the association of lipoprotein(a) levels, measured with an assay independent of apolipoprotein(a) isoform size, with the incidence of future cardiovascular events.
Design, Setting, and Participants Prospective study of 27 791 initially healthy women in the Women's Health Study, enrolled between November 1992 and July 1995 and followed up for 10 years. Lipoprotein(a) level was measured in blood samples obtained at baseline with an assay independent of apolipoprotein(a) isoform size.
Main Outcome Measure Hazard ratios (HRs) for first-ever major cardiovascular events (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization, or cardiovascular deaths).
Results During follow-up, there were 899 incident cardiovascular events. After adjusting for age, smoking, blood pressure, body mass index, total cholesterol, high-density lipoprotein cholesterol, diabetes, hormone use, C-reactive protein, and randomization treatment groups, women in the highest quintile of lipoprotein(a) ( 44.0 mg/dL) were 1.47 times more likely (95% CI, 1.21-1.79; P for trend <.001) to develop cardiovascular events than women in the lowest quintile ( 3.4 mg/dL). This association, however, was due almost entirely to a threshold effect among those with the highest lipoprotein(a) levels. After adjusting for all of the variables listed above, the HR associated with lipoprotein(a) levels exceeding the 90th percentile (65.5 mg/dL) was 1.66 (95% CI, 1.38-1.99); 95th percentile (83 mg/dL), 1.87 (95% CI, 1.50-2.34); and 99th percentile (130.7 mg/dL), 1.99 (95% CI, 1.32-3.00), with almost no risk gradient at lower levels. Associations were strongest among women with low-density lipoprotein cholesterol (LDL-C) above the median level. In this subgroup, the adjusted HR associated with lipoprotein(a) levels exceeding the 90th percentile was 1.81 (95% CI, 1.48-2.23); 95th percentile, 1.93 (95% CI, 1.51-2.48); and 99th percentile, 1.93 (95% CI, 1.21-3.05) (P value for interaction with LDL-C = .001).
Conclusions In this cohort of initially healthy women, extremely high levels of lipoprotein(a) (90th percentile), measured with an assay independent of apolipoprotein(a) isoform size, were associated with increased cardiovascular risk, particularly in women with high levels of LDL-C. However, the threshold and interaction effects observed do not support routine measurement of lipoprotein(a) for cardiovascular stratification in women.
Author Affiliations: Donald W. Reynolds Center for Cardiovascular Research and the Leducq Foundation Center for Vascular Research, Boston, Mass (Drs Suk Danik, Buring, and Ridker); the Center for Cardiovascular Disease Prevention and the Divisions of Preventive Medicine (Drs Suk Danik, Buring, and Ridker) and Cardiology (Drs Suk Danik and Ridker), Brigham and Women's Hospital, and the Department of Laboratory Medicine, Children's Hospital (Dr Rifai), Harvard Medical School, Boston, Mass.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma
Bergmark et al.
J. Lipid Res. 2008;49:2230-2239.
ABSTRACT
| FULL TEXT
Pentanucleotide Repeat Polymorphism, Lipoprotein(a) Levels, and Risk of Ischemic Heart Disease
Kamstrup et al.
J. Clin. Endocrinol. Metab. 2008;93:3769-3776.
ABSTRACT
| FULL TEXT
Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
Merki et al.
Circulation 2008;118:743-753.
ABSTRACT
| FULL TEXT
Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Suk Danik et al.
J Am Coll Cardiol 2008;52:124-131.
ABSTRACT
| FULL TEXT
Role of Lipoprotein(a) in Cardiovascular Disease: Current and Future Perspectives
Berglund and Anuurad
J Am Coll Cardiol 2008;52:132-134.
FULL TEXT
Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease: Large-Scale Prospective Data
Bennet et al.
Arch Intern Med 2008;168:598-608.
ABSTRACT
| FULL TEXT
Rationale, Design, and Methodology of the Women's Genome Health Study: A Genome-Wide Association Study of More Than 25 000 Initially Healthy American Women
Ridker et al.
Clin. Chem. 2008;54:249-255.
ABSTRACT
| FULL TEXT
Lipoprotein(a) and Cardiovascular Disease in Ethnic Chinese: The Chin-Shan Community Cardiovascular Cohort Study
Chien et al.
Clin. Chem. 2008;54:285-291.
ABSTRACT
| FULL TEXT
A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study.
Shiffman et al.
J Am Coll Cardiol 2008;51:444-448.
ABSTRACT
| FULL TEXT
Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study
Kamstrup et al.
Circulation 2008;117:176-184.
ABSTRACT
| FULL TEXT
Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study
Kiechl et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:1788-1795.
ABSTRACT
| FULL TEXT
Increased Serum Lipoprotein(a) Concentrations and Low Molecular Weight Phenotypes of Apolipoprotein(a) Are Associated with Symptomatic Peripheral Arterial Disease
Dieplinger et al.
Clin. Chem. 2007;53:1298-1305.
ABSTRACT
| FULL TEXT
Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease
Jones et al.
Clin. Chem. 2007;53:679-685.
ABSTRACT
| FULL TEXT
Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score
Ridker et al.
JAMA 2007;297:611-619.
ABSTRACT
| FULL TEXT
One Less Screening Test to Order?
JWatch Women's Health 2006;2006:4-4.
FULL TEXT
|
